Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN N versus PEN VEE K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN N versus PEN VEE K.
OMNIPEN-N vs PEN-VEE K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
250-500 mg orally every 6-8 hours for mild to moderate infections; up to 2 g/day for severe infections.
None Documented
None Documented
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 30-60 minutes in adults with normal renal function, prolonged to 3-10 hours in severe renal impairment.
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 60-90% of elimination; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic